home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  September 29, 2016
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 686 active entries

BioStat Solutions, Inc.

5280 Corporate Drive, Suite C200
Frederick, 21703
United States of America, Maryland

Phone: 301.829.4001
Fax: 301.829.4166
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Description:

BioStat Solutions, Inc. (BSSI) is a statistical consulting corporation providing services in biomarker statistics, medical & diagnostic device studies and vaccine development.

Biomarker Statistics:

We offer statistical expertise, from SAP development to reporting, and analytical support, from program creation to validation, on the PGx / biomarker component of studies:

  • Across Phase I-IV clinical trials as well as exploratory studies
  • Across therapeutic areas: Oncology, Diabetes, Neuroscience, Cardiovascular, Autoimmune, Infectious Diseases, Musculoskeletal, and ADME
  • Across commercial assay platforms: SNP genotyping (whole-genome or candidate gene), next generation sequencing (NGS), gene expression (chips and qPCR), immunohistochemistry (IHC) and a wide array of protein assays
  • And we are experienced and adept at dealing with data from novel assay platforms

Biomarker Discovery & Evaluation

  • Analysis of Targeted or High‐Dimensional Biological Data
  • Empirical Evidence to Support Marketable Differentiation Strategies

Patient Stratification

  • Identification of Treatment‐Specific Subgroups
  • Estimation of Disease Subtypes

Integration of Biomarker Programs with Your Portfolio

  • Drug Target Identification
  • Characterization of Mechanism of Action
  • Using Late‐Phase Studies to Inform Early‐Phase Decisions

Medical Countermeasures

The development of medical countermeasures (i.e. drugs, devices, or biologics) for use in biodefense presents unique challenges due to the ethical implications of actively exposing humans to known lethal agents and low frequency of natural occurrence limiting the ability to perform efficacy evaluations in observational studies. Alternative solutions such as the use of animal models or surrogate biomarkers must be developed to predict likely clinical benefits in humans, and these new scientific challenges necessitate tailored analytical strategies.

Challenges of Gaining Licensure

  • Engagement with a cross-functional team of experts
  • Understanding of the requirements set forth in 21 CFR Parts 314 and 601 (FDA Animal Rule)
  • Ability to interact with cross governmental agencies (e.g. FDA, NIAID, DSTL)
  • Selection of appropriate design and methods to demonstrate performance

The Complete Analytical Solution

  • Strategic planning
  • Statistical Analysis Plan (SAP) development
  • Program creation and validation
  • High quality reporting (SARs, regulatory documents, presentations)
  • Representation for interactions with collaborators and governmental agencies

Medical Devices

Medical devices span many spaces and applications, ranging from radiology (e.g., multi-reader multi-case studies) to pathology (e.g., in vitro companion diagnostics built on IHC data). In this complex landscape, it is critical to understand concepts from pre-analytical development through analytical and clinical validation.

Challenges of FDA Approval

  • Engagement with a cross-functional team of experts
  • Understanding the burden of proof for each stage
  • Selection of appropriate design and methods to demonstrate performance

The Complete Analytical Solution

  • Strategic planning
  • Statistical Analysis Plan (SAP) development
  • Program creation and validation
  • High quality reporting (SARs, regulatory documents)
  • FDA representation for statistical component

Extensive Experience

BSSI specializes in the analytical component of complex premarket notifications (510k) and premarket approvals (PMA):

  • Medical devices for use in diagnosis or treatment of disease
  • In vitro diagnostics (IVD)
  • In vitro companion diagnostics


Selected Categories:
Product Company   Service Company
Consulting
- Research
- Strategic
Contract
- Research
- Services

Last update of this entry: May 10, 2016

Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.